Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: relationship between total CYP and CYP3A2

Abstract

It has been reported that infection interferes with drug metabolism, resulting in changes in pharmacokinetics. In this study, we investigated the effects of lipopolysaccharide (LPS) on hepatic total cytochrome P450 (CYP), CYP3A2, and CYP2C11 contents in a transient, LPS-induced, endotoxemia model of rats. In addition, to assess the effects on CYP3A2 activities, the pharmacokinetics of midazolam (CYP3A2 substrate) and 1-OH-midazolam (metabolite of midazolam) were investigated. Hepatic total CYP contents were significantly low until day 3 (P < 0.05) but returned to the control level on day 5. Hepatic CYP3A2 contents were significantly decreased on day 1 until day 5 (P < 0.05) but returned to the control level on day 7. Hepatic CYP2C11 contents were continuously low until day 7, and lowest on day 3. The AUC of 1-OH-midazolam was significantly decreased on day 1 after LPS administration (P < 0.01). In conclusion, LPS (5 mg/kg) challenge decreased hepatic total CYP, CYP3A2, and CYP2C11 contents and also decreased the activities of hepatic CYP3A2. It took at least 7 days for hepatic total CYP and CYP3A2 to recover to control levels, and it was suggested that the changes of hepatic total CYP contents might correlate with those of hepatic CYP3A2 contents and activities. Additionally, it is shown that their changes might reflect the recovery process from inflammation.

Keywords

Lipopolysaccharide total CYP CYP3A2 CYP2C11 liver midazolam

References

Hotchkiss RS , Karl IE The pathophysiology and treatment of sepsis . N Engl J Med 2003; 348: 138-150.

Saitoh T. , Kokue E. , Shimoda M. The impact of acute phase response on the plasma clearance of antipyrine, theophylline and nifedipine in rabbits. J Vet Pharmacol Ther 2000; 23: 153-158.

Lee CC , Lin NT , Hsu YH et al. Inducible nitric oxide synthase inhibition potentiates multiple organ dysfunction induced by endotoxin in conscious rats. J Cardiovasc Pharmacol 2005; 45: 396-403.

Wheeler AP , Bernard GR Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-214.

Kitaichi K. , Li W. , Takagi K. et al. Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide. Antimicrob Agents Chemother 1999; 43: 2697-2701.

Kitaichi K. , Nakayama H. , Ueyama J. et al. Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7. Biochem Pharmacol 2004; 67: 1427-1435.

Takemura S. , Minamiyama Y. , Imaoka S. et al. Hepatic cytochrome P450 is directed inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol 1999; 30: 1035-1044.

Moriguchi J. , Kato R. , Nakagawa M. et al. Effects of lipopolysaccharide on intestinal P-glycoprotein expression and activity. Eur J Pharmacol 2007; 565: 220-224.

Kato R. , Fujiwara A. , Kawai T. et al. Changes in digoxin pharmacokinetics treated with lipopolysaccharide in Wistar rats. Biol Pharm Bull 2008; 31:.

10.

Kato R. , Tokunaga Y. , Kawai T. et al. Effects of CpG-DNA from Escherichia coli on digoxin pharmacokinetics . Biol Pharm Bull 2008; In press.

11.

Chin BE , Thierry B. , Gianni C. et al. Oral administration of a low dose of midazolam (75 µg) as an in vivo probe for CTP3A activity. Eur J Clin Pharmacol 2004; 60: 237-246.

12.

Eeckhoudt SL , Horsmans Y. , Verbeeck RK Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 2002; 32: 975-984.

13.

Higashikawa F. , Murakami T. , Kaneda T. et al. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats. J Pharm Pharmacol 1999; 51: 405-410.

14.

Bittner B. , Gonzalez RC , Isel H. et al. Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. Eur J Pharm Biopharm 2003; 56: 143-146.

15.

Fujishima S. , Akikawa N. Pathophysiolosy of hypercytokinemia. Nippon Rinsho 2004; 62: 2004-2012.